France: AFB launches second fund with first close at €86m

Advent France Biotechnology (AFB), a regulated investment company focused on life sciences, has announced the first close of its second fund at €86m (US$102m). The European Investment Fund (EIF) and the French Seed Fund 2, managed on behalf of the French State by Bpifrance, participated in the fund, along with corporate ventures including Boehringer Ingelheim…

You must be a HMI Subscriber to view this content.

Subscribe Now »